Cofactor Genomics said it has made an agreement with NCI, along with agreements regarding research groups at three other academic and pharma institutions, to demonstrate the clinical utility of the company’s immune-profiling assay, Cofactor Paragon.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe